openPR Logo
Press release

Trends in the Dysmenorrhea Treatment Market 2016 - 2026

02-14-2018 06:07 AM CET | Health & Medicine

Press release from: Future Market Insights

/ PR Agency: Future Market Insights

Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause pain and decrease blood flow and oxygen to the uterus. A wide variety of underlying condition can contribute to menstrual disorders. To pinpoint the cause, physician generally rely on the patient’s medical history, physical examination, and laboratory test. This determines the exact cause of menstrual disorder and helps the physician to plan appropriate treatment. This has grabbed the attention of dysmenorrhea drug manufacturers to develop and commercialize more effective medicines to treat dysmenorrhea.

Dysmenorrhea Treatment Market: Drivers and Restraints

Increasing incidence of dysmenorrhea, high awareness level and growing concern about dysmenorrhea among females from developed countries, involvement of companies for developing innovative drugs, and government campaigns with respect to women healthcare are effectively endorsing the growth of dysmenorrhea treatment market. However, side effect and complications of long term treatment, substantial morbidity of dysmenorrhea which leads to inadequate treatment, and traditional values of families would hinder the growth of dysmenorrhea treatment market.

Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-1312

Dysmenorrhea Treatment Market: Segmentation

The global dysmenorrhea treatment market is segmented based type of disease, and therapeutic class.

Based type of diseases, the global dysmenorrhea market is segmented into the following:

Primary dysmenorrhea
Secondary dysmenorrhea
Endometriosis
Adenomyosis
Uterine myomas
Endometrial polyps
Cervical stenosis
Obstructive malformations of genital tract

Based on therapeutic class, the global dysmenorrhea treatment market is segmented into the following:

Non-hormonal medical treatment
Non-steroidal anti-inflammatory drugs (NSAIDs)
Non-selective NSAIDs
COX-2 inhibitors
Transdermal glyceryl trinitrate
Over-the-counter (OTC) medications
Hormonal medicine treatment
Combined oral contraceptive
Progestin regimens
Levonorgestrel intrauterine system (LN-IUS)
Surgical options
Laparoscopy
Hysterectomy
Presacral neurectomy
Laparoscopic uterosacral nerve ablation (LUNA)
Intrauterine device (IUD)

Dysmenorrhea Treatment Market: Overview

By non-hormonal medical treatment, NSAID’s such as Ibuprofen and Naproxen, are most commonly used drugs for the treatment of dysmenorrhea and hold prominent share owing to its lower cost and easy availability. COX-2 inhibitors have also proven effective in relieving pain, and would gain prominence in developed countries. Physicians also prescribe hormonal medicine treatment such as contraceptive pills to regularize the menstrual bleeding will gain good market share in emerging countries.

Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-1312

Dysmenorrhea Treatment Market: Region-wise Outlook

Geographically, the North America accounts for the largest market share followed by Europe, in terms revenues and research activities. In addition. APEI market is also expected to grow significantly in the coming years owing to support of government and non-profit organizations in awareness campaigns, growing number of patients suffering with dysmenorrhea, and high disposable income.

Dysmenorrhea Treatment Market: Key Players

Key companies operational in dysmenorrhea treatment market are Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, Terramedic, Inc., and others.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Trends in the Dysmenorrhea Treatment Market 2016 - 2026 here

News-ID: 942200 • Views:

More Releases from Future Market Insights

Crude Sulfate Turpentine Market to Reach USD 1.1 Billion by 2036 as Bio-Based Terpene Demand and ISCC Certification Reshape Industry Standards
Crude Sulfate Turpentine Market to Reach USD 1.1 Billion by 2036 as Bio-Based Te …
The global crude sulfate turpentine market is entering a structural transformation phase, projected to expand from USD 653 million in 2026 to USD 1.1 billion by 2036, registering a CAGR of 5.3%. According to Future Market Insights, growth is being driven by the accelerating shift toward bio-based pinene and terpene derivatives across fragrance, adhesive, coatings, and sustainable solvent applications. The market's expansion is fundamentally linked to its upstream integration with the
Ascorbic Acid Market to Reach USD 3.0 Billion by 2036 as Premium Certification and API Integration Reshape Supply Chains
Ascorbic Acid Market to Reach USD 3.0 Billion by 2036 as Premium Certification a …
The global ascorbic acid market is entering a structurally transformative decade, projected to expand from USD 1.7 billion in 2026 to USD 3.0 billion by 2036, registering a steady CAGR of 5.7%. According to Future Market Insights (FMI), growth is being driven by rising pharmaceutical reliance on vitamin C APIs, expanding functional food fortification, and the premiumization of cosmetic-grade vitamin C derivatives. Ascorbic acid's inclusion on the World Health Organization (WHO)
Functional Dairy Products Market to Reach USD 78.9 Billion by 2036 as Clinical-Grade Nutrition and GLP-1 Driven Protein Demand Reshape Industry Dynamics
Functional Dairy Products Market to Reach USD 78.9 Billion by 2036 as Clinical-G …
The global functional dairy products market is entering a structurally transformative decade, projected to expand from USD 50.8 billion in 2026 to USD 78.9 billion by 2036, reflecting a steady CAGR of 4.5%. According to Future Market Insights (FMI), the category's next growth phase is no longer defined solely by probiotic yogurt adoption but by the convergence of microbiome science, medical nutrition integration, and the rapid emergence of GLP-1 medication
Short-chain Fructooligosaccharides Market to Reach USD 1.7 Billion by 2036 as Prebiotic Science and Sugar Reformulation Strategies Accelerate
Short-chain Fructooligosaccharides Market to Reach USD 1.7 Billion by 2036 as Pr …
The global short-chain fructooligosaccharides market is entering a structurally transformative decade, projected to expand from USD 869 million in 2026 to USD 1.7 billion by 2036, registering a steady CAGR of 7.0%. According to Future Market Insights (FMI), this expansion is underpinned by three structural forces: global sugar reduction mandates, regulatory validation of prebiotics, and the integration of scFOS into infant nutrition formulations designed to approximate human milk oligosaccharide (HMO)

All 5 Releases


More Releases for Dysmenorrhea

Dysmenorrhea Market Share, Epidemiology, Analysis & Trends 2023-2033
Market Overview:  The dysmenorrhea market is expected to exhibit a CAGR of 5.67% during 2023-2033. The dysmenorrhea market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major
Dysmenorrhea - Drug Pipeline Landscape, 2022
Global Dysmenorrhea Market report from Global Insight Services is the single authoritative source of intelligence on Dysmenorrhea market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and
Dysmenorrhea - Drug Pipeline Landscape, 2022
Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of menstru*tion and last for the first few days of
Dysmenorrhea - Drug Pipeline Landscape, 2022
Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of and last for the first few days of
Dysmenorrhea Treatment Market: Market Intelligence and Market Trends
Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause
Dysmenorrhea Treatment Market size and forecast, 2016-2026
Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause